Key areas of focus include: Regulatory and Scientific Foundations: Current FDA scientific thinking on generic GLP-1 product development, Product-Specific Guidance (PSG) development, and in vivo BE studies for GLP-1 oral products Active Pharmaceutical Ingredient (API) Characterization and Manufacturing: Comprehensive approaches to demonstrating API sameness, analytical characterization strategies, impurity profiling, and sameness assessment for peptide products Recombinant Peptide Production: Best practices for controlling host cell impurities, regulatory expectations, and risk assessment strategies Oral GLP-1 Formulation Development: Formulation and delivery innovations, bioequivalence study design for highly variable products, absorption enhancement technologies, and drug product quality expectations Device User Interface and Human Factors: Comparative analyses (CA) of device user interfaces, Comparative Use Human Factors (CUHF) study design and case examples, alternative approaches, and device platform strategies Device Quality and Integration: Quality considerations for generic injectors, drug-device interface and compatibility, manufacturing quality control, and submission coordination strategies Join us for an immersive two-day experience featuring presentations from leading experts in regulatory agencies, pharmaceutical industry, and academia
Semaglutide does appear in your body in ways that matter, particularly in standard blood work
Notably, epidemiological data indicate that Asian populations develop diabetes at a significantly younger age than White populations, exhibiting elevated risks of disease-related complications and mortality, thereby imposing a considerable healthcare burden [117]
Results depend on combining the drink with a calorie-controlled diet and regular exercise
